Bayer's Glaucoma Drug Push
Bayer Acquires Perfuse Therapeutics in a Deal Potentially Worth $2.45 Billion, Expanding Ophthalmology Pipeline
Bayer AG has completed its acquisition of Perfuse Therapeutics, a South San Francisco biotech focused on eye diseases caused by restricted blood flow. The deal is worth up to $2.45 billion and marks one of Bayer's boldest pharmaceutical bets in years, according to Business Wire.
Perfuse's lead drug, PER-001, is a first-of-its-kind implant that targets a key cause of vision loss in glaucoma and diabetic retinopathy. If it succeeds, it could reach over 226 million patients worldwide, Stock Titan reported.
PER-001 Targets the Root Cause of Blindness
Most glaucoma drugs today focus only on lowering eye pressure. But up to 25% of patients keep losing vision even when pressure is controlled. Perfuse's theory: restricted blood flow to the optic nerve — driven by a protein called endothelin-1 — is killing cells. PER-001 blocks that protein directly inside the eye, Business Wire reported.
In Phase 2 trials completed in June 2025, 37.5% of high-dose glaucoma patients saw at least a 7-decibel improvement in retinal function. That is a meaningful jump for a disease where any reversal of vision loss is rare. Bayer's head of business development, Dr. Juergen Eckhardt, called PER-001 the potential "first disease-modifying treatment" for glaucoma.
A Twice-Yearly Shot Could Replace Daily Eye Drops
Current glaucoma treatment requires daily eye drops. Studies show up to 50% of patients fail to use them correctly. Perfuse's implant needs only two injections per year. That could dramatically improve outcomes for millions of people who struggle with daily regimens, according to Stock Titan.
The drug targets both glaucoma — which affects 80 million people globally — and diabetic retinopathy, which affects another 146 million. Stefan Oelrich, Bayer's pharmaceuticals chief, said the deal "complements our expertise in ophthalmology and reinforces our commitment to developing urgently needed therapies."
Bayer Bets Big as Its Top Eye Drug Fades
Bayer's biggest ophthalmology drug, Eylea, brought in roughly €3.1 billion in 2025. But sales fell 5.9% year-on-year as cheaper copycat drugs entered European markets. The Perfuse deal gives Bayer a next-generation candidate to protect its position in eye care, according to Market Screener.
CEO Bill Anderson has shifted Bayer's strategy toward smaller, targeted biotech deals after the company's costly Monsanto acquisition saddled it with legal liabilities. The Perfuse deal fits that mold — a focused, high-upside bet in a field where Bayer already has sales teams and relationships in place.
Deal Structure Loads Most Risk Onto Milestones
The upfront payment is roughly $300 million — a small fraction of the $2.45 billion total. The remaining $2.15 billion comes only if PER-001 hits future clinical and regulatory milestones. That structure puts most of the financial risk on Perfuse's original investors, not Bayer, Financial Content noted.
Perfuse founder and CEO Dr. Sevgi Gurkan said the deal allows Bayer to "unlock the full potential of PER-001 to change the trajectory of human blindness." BofA Securities and Baker McKenzie advised Bayer. Centerview Partners and Goodwin Procter represented Perfuse, according to Business Wire.
Sentiment
NeutralPublishers
4
Articles
3
Reach
4
